Literature DB >> 28130683

Early diagnosis of early-onset sarcoidosis: a case report with functional analysis and review of the literature.

Yusuke Takeuchi1, Tomonari Shigemura2, Norimoto Kobayashi2, Naoe Kaneko3, Tomoyuki Iwasaki3, Kisei Minami4, Keiko Kobayashi5, Junya Masumoto3, Kazunaga Agematsu5.   

Abstract

This study examined the pathogenesis of early-onset sarcoidosis (EOS) in a patient with a rare NOD2 mutation and surveyed the literature to identify the hallmark features for early diagnosis. An infant girl suffering from prolonged fever and skin rash of multiple pinkish papules and subsequent erythema nodosum was referred to our institution. Skin biopsy and DNA sequencing were performed along with cytokine profiling of the patient's serum and stimulated mononuclear cells. NF-κB activation was analyzed using transfected cells. Multiple non-caseating granuloma inclusions were recognized in biopsy specimens obtained from the patient's rash. DNA sequencing revealed a very rare heterozygous Met513Thr (M513T) mutation in NOD2. Mononuclear cells produced a low amount of IL-1β upon stimulation as compared with normal control cells. Mutated NOD2 transfection enhanced NF-κB activation. We suspected that the M513T mutation in NOD2 decreased IL-1β production and enhanced NF-κB activation, which was likely responsible for the patient's granuloma involvement. A comprehensive review of the literature on 30 cases of sporadic type of EOS revealed that all patients had cutaneous manifestations, with all but one displaying granulation. A majority of EOS patients have R334W/Q. But about half of sporadic EOS had NOD2 mutations other than R334W/Q, as in the present case. Accordingly, skin rash with granuloma formation and specific NOD2 mutations may represent early diagnostic hallmarks of EOS in infants with persistent inflammation.

Entities:  

Keywords:  Early-onset sarcoidosis; IL-1β; NF-κB activation; NOD2/CARD15

Mesh:

Substances:

Year:  2017        PMID: 28130683     DOI: 10.1007/s10067-017-3544-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  45 in total

1.  Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation.

Authors:  Nobuo Kanazawa; Satoko Matsushima; Naotomo Kambe; Takao Tachibana; Sonoko Nagai; Yoshiki Miyachi
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

2.  Early-onset sarcoidosis mimicking refractory cutaneous histiocytosis.

Authors:  Shouichi Ohga; Kiyomi Ichino; Kazunori Urabe; Masataka Ishimura; Hidetoshi Takada; Ryuta Nishikomori; Masutaka Furue; Toshiro Hara
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

3.  Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15.

Authors:  Satoshi Okada; Nakao Konishi; Miyuki Tsumura; Kenichiro Shirao; Shin'ichiro Yasunaga; Hidemasa Sakai; Ryuta Nishikomori; Yoshihiro Takihara; Masao Kobayashi
Journal:  Rheumatology (Oxford)       Date:  2009-04-09       Impact factor: 7.580

4.  A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene.

Authors:  Hidemasa Sakai; Shusaku Ito; Ryuta Nishikomori; Yuuki Takaoka; Tomoki Kawai; Megumu Saito; Ikuo Okafuji; Takahiro Yasumi; Toshio Heike; Tatsutoshi Nakahata
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

5.  Distinguishing between the innate immune response due to ocular inflammation and infection in a child with juvenile systemic granulomatous disease treated with anti-TNFα monoclonal antibodies.

Authors:  Srilakshmi M Sharma; Tammy M Martin; Carlos D Rosé; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Rheumatology (Oxford)       Date:  2011-01-27       Impact factor: 7.580

6.  Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period.

Authors:  Johanna Stoevesandt; Henner Morbach; Tammy M Martin; Manfred Zierhut; Hermann Girschick; Henning Hamm
Journal:  Pediatr Dermatol       Date:  2010 Jan-Feb       Impact factor: 1.588

7.  Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene.

Authors:  Veena Rao Raiji; Marijean M Miller; L K Jung
Journal:  J AAPOS       Date:  2011-04       Impact factor: 1.220

8.  Immunohistochemical evidence of specific iris involvement in Blau syndrome.

Authors:  Stella C Paparizos; Debra A Goldstein; Rachida A Bouhenni; Scott Steiner; Jeffrey J Dunmire; Deepak P Edward
Journal:  Ocul Immunol Inflamm       Date:  2012-12       Impact factor: 3.070

9.  A sporadic case of early-onset sarcoidosis resembling Blau syndrome due to the recurrent R334W missense mutation on the NOD2 gene.

Authors:  P Coto-Segura; S Mallo-Garcia; M Costa-Romero; J I Arostegui; J Yague; E Ramos-Polo; J Santos-Juanes
Journal:  Br J Dermatol       Date:  2007-10-04       Impact factor: 9.302

10.  Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.

Authors:  Gabriele Simonini; Zhaohui Xu; Roberto Caputo; Cinzia De Libero; Ilaria Pagnini; Virginia Pascual; Rolando Cimaz
Journal:  Arthritis Rheum       Date:  2013-02
View more
  3 in total

Review 1.  Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.

Authors:  Tomoko Matsuda; Naotomo Kambe; Riko Takimoto-Ito; Yoko Ueki; Satoshi Nakamizo; Megumu K Saito; Syuji Takei; Nobuo Kanazawa
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

2.  Unique Variant of NOD2 Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis.

Authors:  Michael P Whyte; Emilina Lim; William H McAlister; Gary S Gottesman; Lien Trinh; Deborah J Veis; Vinieth N Bijanki; Matthew G Boden; Angela Nenninger; Steven Mumm; David Buchbinder
Journal:  J Bone Miner Res       Date:  2018-07-30       Impact factor: 6.741

3.  A Case of Sporadic Blau Syndrome with an Uncommon Clinical Course.

Authors:  Miyoko Imayoshi; Yoshiyasu Ogata; Shuichi Yamamoto
Journal:  Case Rep Rheumatol       Date:  2018-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.